Association of Statin Use and Oncological Outcomes After Neoadjuvant Radiotherapy in Patients With Rectal Cancer

Tina Fransgaard, Jesper Hallas, Lau Caspar Thygesen, Ismail Gögenur

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.

Original languageEnglish
JournalAnticancer Research
Volume39
Issue number4
Pages (from-to)2177-2182
ISSN0250-7005
DOIs
Publication statusPublished - Apr 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rectal Neoplasms
Disease-Free Survival
Propensity Score
Cohort Studies
Outcome Assessment (Health Care)

Keywords

  • chemoradiotherapy
  • Rectal cancer
  • statins
  • Humans
  • Middle Aged
  • Male
  • Treatment Outcome
  • Chemoradiotherapy
  • Aged, 80 and over
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
  • Female
  • Neoadjuvant Therapy
  • Aged
  • Rectal Neoplasms/mortality

Cite this

@article{5c8122a8b7ff40d5b1816221f4512b1d,
title = "Association of Statin Use and Oncological Outcomes After Neoadjuvant Radiotherapy in Patients With Rectal Cancer",
abstract = "AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95{\%} confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95{\%} CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95{\%} CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.",
keywords = "chemoradiotherapy, Rectal cancer, statins, Humans, Middle Aged, Male, Treatment Outcome, Chemoradiotherapy, Aged, 80 and over, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Female, Neoadjuvant Therapy, Aged, Rectal Neoplasms/mortality",
author = "Tina Fransgaard and Jesper Hallas and Thygesen, {Lau Caspar} and Ismail G{\"o}genur",
year = "2019",
month = "4",
doi = "10.21873/anticanres.13332",
language = "English",
volume = "39",
pages = "2177--2182",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

Association of Statin Use and Oncological Outcomes After Neoadjuvant Radiotherapy in Patients With Rectal Cancer. / Fransgaard, Tina; Hallas, Jesper; Thygesen, Lau Caspar; Gögenur, Ismail.

In: Anticancer Research, Vol. 39, No. 4, 04.2019, p. 2177-2182.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Association of Statin Use and Oncological Outcomes After Neoadjuvant Radiotherapy in Patients With Rectal Cancer

AU - Fransgaard, Tina

AU - Hallas, Jesper

AU - Thygesen, Lau Caspar

AU - Gögenur, Ismail

PY - 2019/4

Y1 - 2019/4

N2 - AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.

AB - AIM: The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer. PATIENTS AND METHODS: The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality. RESULTS: A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups. CONCLUSION: The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.

KW - chemoradiotherapy

KW - Rectal cancer

KW - statins

KW - Humans

KW - Middle Aged

KW - Male

KW - Treatment Outcome

KW - Chemoradiotherapy

KW - Aged, 80 and over

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Female

KW - Neoadjuvant Therapy

KW - Aged

KW - Rectal Neoplasms/mortality

U2 - 10.21873/anticanres.13332

DO - 10.21873/anticanres.13332

M3 - Journal article

VL - 39

SP - 2177

EP - 2182

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -